相关实验视频

Updated: Jun 11, 2025

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

在类风湿性关节炎中中和性血管类蛋白4单克隆抗体的骨保护作用

Liqing Ke¹, Qifei He², Jing Qu³

¹Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.

Molecular therapy : the journal of the American Society of Gene Therapy

|October 5, 2024

概括

血管蛋白样蛋白4 (ANGPTL4) 的升高与类风湿性关节炎 (RA) 有关. 针对它的片段,cANGPTL4,用抗体减少了RA模型中的炎症和骨损失,这表明了一种新的治疗方法.

科学领域:

免疫学免疫学免疫学
类风湿病学类风湿病学
分子生物学分子生物学

背景情况:

类风湿性关节炎 (RA) 仍然是一个重大的治疗挑战,疾病的发展可能与血管蛋白样蛋白4 (ANGPTL4) 的过度生产有关.
最初以脂质代谢而闻名的ANGPTL4产生了参与血管生成和炎症的C端片段 (cANGPTL4).

研究的目的:

为了研究ANGPTL4在类风湿性关节炎发病过程中的作用.
在RA模型中评估针对cANGPTL4的治疗潜力.

主要方法:

在RA患者的血清和突组织中量化ANGPTL4水平.
在动物模型中,在原诱导性关节炎和辅助剂诱导性关节炎 (AIA) 中给予对cANGPTL4 (anti-cANGPTL4 Ab) 的中和抗体.
从AIA模型中对突组织进行转录和蛋白质分析.
在RA-纤维细胞样同胞细胞 (RA-FLS) 中分析sirtuin 1/核因子-κB信号通路.

主要成果:

与对照组相比,RA患者的ANGPTL4水平显著更高.
在RA动物模型中,抗cANGPTL4 Ab治疗减少了炎症和骨损失.
在AIA模型中,抗体抑制了纤维细胞样同胞细胞 (FLS) 移民和骨质细胞形成.
从机制上讲,抗cANGPTL4 Ab通过sirtuin 1/核因子-κB通路抑制了RA-FLS中TNF-α诱导的炎症级联,并阻止了FLS诱导的骨质细胞激活.

结论:

ANGPTL4 是一种潜在的风湿性关节炎诊断生物标志物.
用中和抗体向cANGPTL4代表了对RA的有前途的治疗策略.

关键词:

ANGPTL4 在线观看生物疗法是一种生物疗法.保护骨保护骨保护骨这是一种炎症炎症炎症炎症.类风湿性关节炎类风湿性关节炎

更多相关视频

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...